Pressure Biosciences 

Pressure BioSciences, Inc. (PBI) provides cutting-edge pressure-driven platform solutions to markets across North America, Europe, and Asia. At its core is the proprietary Pressure Cycling Technology (PCT), which utilizes alternating hydrostatic pressure, oscillating between ambient and exceedingly high levels, to precisely regulate molecular processes within various biological specimens. These specimens include cells and tissues originating from human, animal, plant, and microbial organisms. PBI's instrumentation portfolio features a suite of Barocycler devices, such as the 2320EXT, HUB880, HUB440, and The Shredder SG3. Beyond its primary instruments, the firm also supplies cell disruption apparatus, associated components, and expendable items. Furthermore, PBI provides Barocycler-compatible consumables, including PCT MicroTubes, PCT MicroCaps, the PCT-Micro Pestle, and specialized pressure lysis tubes, alongside comprehensive application-specific kits that bundle necessary consumables and reagents. Its clientele encompasses researchers within academic institutions, governmental bodies, biotechnology enterprises, pharmaceutical corporations, and other life science organizations. PBI actively collaborates with esteemed partners such as RedShiftBio Inc., Inova Schar Cancer Center, NYU, Leica Microsystems, GmbH, the Steinbeis Centre for biopolymer analysis and biological mass spectrometry, The Ohio State University, the University of Delaware, and Cedars Sinai Medical Center. Originally established in 1978 as Boston Biomedica, Inc., the company is headquartered in South Easton, Massachusetts. Effective August 2, 2022, Pressure BioSciences, Inc. began operating as a subsidiary of Emergent Health Corp.